Persones / Equip Humà

Emma Barroso Fernández

Buscador de publicacions

Publicacions

  • Aguilar-Recarte D, Barroso E, Zhang M, Rada P, Pizarro J, Peña L, Palomer FX, Valverde ÁM, Wahli W and Vazquez M.

    A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects.

    PHARMACOLOGICAL RESEARCH . 187: 106578-106578. Nº de cites: 15

    [doi:10.1016/j.phrs.2022.106578]

  • Aguilar-Recarte D, Barroso E, Palomer FX, Wahli W and Vazquez M.

    Knocking on GDF15?s door for the treatment of type 2 diabetes mellitus

    TRENDS IN ENDOCRINOLOGY AND METABOLISM . 33(11): 741-754. Nº de cites: 18

    [doi:10.1016/j.tem.2022.08.004]

  • García-Torra V, Cano A, Espina M, Ettcheto M, Camins A, Barroso E, Vazquez M, García ML, Sánchez-López E and Souto EB.

    State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks.

    Toxics . 9(8): 195. Nº de cites: 21

    [doi:10.3390/toxics9080195]

  • Aguilar-Recarte D, Barroso E, Gumá L, Pizarro J, Peña L, Ruart M, Palomer FX, Wahli W and Vazquez M.

    GDF15 mediates the metabolic effects of PPARß/d by activating AMPK.

    CELL REPORTS . 36(6): 109501-109501. Nº de cites: 52

    [doi:10.1016/j.celrep.2021.109501]

  • Barroso E, Rodríguez-Rodríguez R, Zarei M, Pizarro-Degado J, Planavila A, Palomer FX, Villarroya-Gombau F and Vazquez M.

    SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1 alpha-LIPIN 1 pathway and increasing CD36 through Nrf2

    CELL COMMUNICATION AND SIGNALING . 18(1): 147-147. Nº de cites: 27

    [doi:10.1186/s12964-020-00640-8]

  • Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis

    TRENDS IN PHARMACOLOGICAL SCIENCES . 41(3): 199-208. Nº de cites: 68

    [doi:10.1016/j.tips.2019.12.005]

  • Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya-Gombau F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M.

    SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.

    signal transduction and targeted therapy . 5(1): 14-14. Nº de cites: 111

    [doi:10.1038/s41392-020-0114-1]

  • Rodríguez-Calvo R, Girona J, Rodríguez M, Samino S, Barroso E, de Gonzalo-Calvo D, Guaita-Esteruelas S, Heras M, van der Meer RW, Lamb HJ, Yanes O, Correig X, Llorente-Cortés V, Vazquez M and Masana L.

    Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes

    METABOLISM-CLINICAL AND EXPERIMENTAL . 96: 12-21. Nº de cites: 36

    [doi:10.1016/j.metabol.2019.04.007]

  • Zarei M, Pujol E, Quesada T, Villarroya-Gombau F, Barroso E, Vázquez S, Pizarro J, Palomer FX and Vazquez M.

    Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

    BRITISH JOURNAL OF PHARMACOLOGY . 176(13): 2292-2305. Nº de cites: 14

    [doi:10.1111/bph.14678]

  • Zarei M, Barroso E, Palomer FX, Escolà-Gil JC, Cedó L, Wahli W and Vazquez M.

    Pharmacological PPARß/d activation upregulates VLDLR in hepatocytes.

    Clinica e Investigacion en Arteriosclerosis . 31(3): 111-118. Nº de cites: 10

    [doi:10.1016/j.arteri.2019.01.004]